echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis "Eltrombopag" approved for new indications in China

    Novartis "Eltrombopag" approved for new indications in China

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 20, Novartis announced that the new indication of Eltrombopag ethanolamine tablets was approved in China for the treatment of chronic immune (idiopathic) children aged 6-11 who have not responded well to glucocorticoids and immunoglobuli.


    Immune thrombocytopenia (ITP), also known as idiopathic thrombocytopenic purpura, is an acquired autoimmune hemorrhagic disease characterized by isolated peripheral blood platelet count reduction without a clear cau.


    At present, glucocorticoids and intravenous immune globulin are the first-line therapy for ITP, and thrombopoietic drugs, including recombinant human thrombopoietin (rhTPO), eltrombopag, e.


    Novartis Eltrombopag ethanolamine tablets were approved in China in 2017 for adult ITP patients who have not responded well to glucocorticoids, immunoglobulins, e.


    In recent years, China has attached great importance to the prevention and treatment of children's blood diseases and malignant tumors, and has issued a series of policies to escort the health of childr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.